Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 7, 2010, Pages 2974-2978

  Bilgrami, I ^a   Roberts, J A ^b   Wallis, S C ^b   Thomas, J ^a   Davis, J ^c   Fowler, S ^a   Goldrick, P B ^a   Lipman, J ^b  

^a ROYAL DARWIN HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ADULT; APACHE; ARTICLE; BURKHOLDERIA PSEUDOMALLEI; CLINICAL ARTICLE; CONTINUOUS HEMOFILTRATION; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SEPSIS; CRITICAL ILLNESS; HEMOFILTRATION; MICROBIOLOGY; PROCEDURES; PROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; HEMOFILTRATION; HUMANS; PROSPECTIVE STUDIES; SEPSIS; THIENAMYCINS;

EID: 77953794043     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01582-09     Document Type: Article

References (26)

1. Ariano, R. E., A. Nyhlen, J. P. Donnelly, D. S. Sitar, G. K. Harding, and S. A. Zelenitsky. 2005. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann. Pharmacother. 39:32-38.
2. Bone, R. C., R. A. Balk, F. B. Cerra, R. P. Dellinger, A. M. Fein, W. A. Knaus, R. M. Schein, and W. J. Sibbald. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655.
3. Bouman, C. S., H. M. Oudemans-van Straaten, M. J. Schultz, and M. B. Vroom. 2007. Hemofiltration in sepsis and systemic inflammatory response syndrome: the role of dosing and timing. J. Crit. Care 22:1-12.
4. Bugge, J. F. 2001. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol. Scand. 45:929-934.
5. Cheng, A. C., and B. J. Currie. 2005. Melioidosis: epidemiology, pathophysiology, and management. Clin. Microbiol. Rev. 18:383-416.
6. Chimata, M., M. Nagase, Y. Suzuki, M. Shimomura, and S. Kakuta. 1993. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob. Agents Chemother. 37:229-233.
7. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug.' Nat. Rev. Microbiol. 2:289-300.
8. Finfer, S., R. Bellomo, J. Lipman, C. French, G. Dobb, and J. Myburgh. 2004. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med. 30:589-596.
9. Giles, L. J., A. C. Jennings, A. H. Thomson, G. Creed, R. J. Beale, and A. McLuckie. 2000. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit. Care Med. 28:632-637.
10. Hurst, M., and H. M. Lamb. 2000. Meropenem: a review of its use in patients in intensive care. Drugs 59:653-680. (Pubitemid 30213867)
11. Isla, A., J. Maynar, J. A. Sanchez-Izquierdo, A. R. Gascon, A. Arzuaga, E. Corral, and J. L. Pedraz. 2005. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients. J. Clin. Pharmacol. 45:1294-1304.
12. Jenney, A. W., G. Lum, D. A. Fisher, and B. J. Currie. 2001. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int. J. Antimicrob. Agents 17:109-113.
13. Krueger, W. A., G. Neeser, H. Schuster, T. H. Schroeder, E. Hoffmann, A. Heininger, H. J. Dieterich, H. Forst, and K. E. Unertl. 2003. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration. Chemotherapy 49:280-286.
14. Krueger, W. A., T. H. Schroeder, M. Hutchison, E. Hoffmann, H. J. Dieterich, A. Heininger, C. Erley, A. Wehrle, and K. Unertl. 1998. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob. Agents Chemother. 42:2421-2424.
15. Kuti, J. L., and D. P. Nicolau. 2005. Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment. Chemotherapy 51:211-216.
16. Levy, E. M., C. M. Viscoli, and R. I. Horwitz. 1996. The effect of acute renal failure on mortality. A cohort analysis. JAMA 275:1489-1494.
17. Li, C., X. Du, J. L. Kuti, and D. P. Nicolau. 2007. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob. Agents Chemother. 51:1725-1730.
18. Roberts, J. A., and J. Lipman. 2009. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med. 37:840-851.
19. Roberts, J. A., S. Webb, D. Paterson, K. M. Ho, and J. Lipman. 2009. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit. Care Med. 37:2071-2078.
20. Rohwedder, R., T. Bergan, S. B. Thorsteinsson, and H. Scholl. 1990. Transintestinal elimination of ciprofloxacin. Chemotherapy 36:77-84.
21. Tegeder, I., F. Neumann, F. Bremer, K. Brune, J. Lotsch, and G. Geisslinger. 1999. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin. Pharmacol. Ther. 65:50-57.
22. Thalhammer, F., and W. H. Horl. 2000. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. Clin. Pharmacokinet. 39:271-279.
23. Thalhammer, F., P. Schenk, H. Burgmann, I. El Menyawi, U. M. Hollenstein, A. R. Rosenkranz, G. Sunder-Plassmann, S. Breyer, and K. Ratheiser. 1998. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob. Agents Chemother. 42:2417-2420.
24. Uchino, S., J. A. Kellum, R. Bellomo, G. S. Doig, H. Morimatsu, S. Morgera, M. Schetz, I. Tan, C. Bouman, E. Macedo, N. Gibney, A. Tolwani, and C. Ronco. 2005. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294:813-818.
25. Valtonen, M., E. Tiula, J. T. Backman, and P. J. Neuvonen. 2000. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J. Antimicrob. Chemother. 45:701-704.
26. Ververs, T. F., A. van Dijk, S. A. Vinks, P. J. Blankestijn, J. F. Savelkoul, J. Meulenbelt, and F. T. Boereboom. 2000. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit. Care Med. 28:3412-3416.